ATC codes: J01GA01
Multi-drug resistant Mycobacterium tuberculosis ICD11 code: ML32.00
Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
EML status history
Also recommended for children
The recommendation is for this specific medicine
Patents have expired in most jurisdictions
Read more about patents.
Expert Committee recommendation
The Expert Committee recommended the deletion of streptomycin powder for injection from the core list of the EML as a first-line antituberculosis treatment option, noting the advice from the WHO TB department that it is no longer recommended as first-line treatment. The Committee noted that streptomycin remains in the Complementary List of the EML and EMLc for second-line use in multidrug-resistant (MDR-TB) tuberculosis.
Streptomycin is currently included in the core list of the EML under Section 6.2.4 for first-line treatment of tuberculosis. It is also included in the Complementary List of the EML and EMLc as a reserve second-line drug for MDR-TB.
Public health relevance
In February 2017, the WHO Guidelines Review Committee approved the new WHO Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update (in press at that time). The updated guidelines no longer recommend the use of streptomycin as a component of first-line antituberculosis therapy but reserve its use as a potential option in second-line regimens for drug-resistant disease.
Cost / cost effectiveness
Refer to the summary for deletion of ofloxacin for recommendations regarding the use of streptomycin in MDR-TB and rifampicin-resistant (RR-TB) disease in current WHO guidelines.
The current listing of streptomycin on the Complementary List of the EML and EMLc as a reserve second-line drug for treatment of MDR-TB will be retained.